HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting 漢康生技成功舉辦SAB科學顧問委員會會議

HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.漢康生技（HanchorBio Inc.），一家專注於腫瘤免疫治療新藥研發與臨床的全球生技公司，今日宣佈其自主研發的創新融合蛋白HCB101獲得美國食品藥物管理局（FDA）授予新藥臨床試驗（IND）許可，即將開展多地區多中心的臨床試驗。此藥將用於治療晚期實體瘤及復發難治癒的非霍奇金淋巴瘤。